Efficacy and safety of low-dose oral minoxidil in the management of androgenetic alopecia
Authors:
- 22 January 2024
- journal article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 25 (2) , 139-147
Abstract
No abstract availableThis publication has 65 references indexed in Scilit:
- Safety of Low-Dose Oral Minoxidil in Patients With Hypertension and Arrhythmia: A Multicenter Study of 264 PatientsActas Dermo-Sifiliograficas, 2023
- Retrospective review of oral and topical minoxidil for cancer treatment-induced hair lossArchives of Dermatological Research, 2023
- The state‐of‐the‐art in the management of androgenetic alopecia: A review of new therapies and treatment algorithmsJEADV Clinical Practice, 2022
- Serious Adverse effects From Compounding Errors With Low-Dose Oral Minoxidil for Alopecia TreatmentActas Dermo-Sifiliograficas, 2022
- Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male PatientsJAMA Dermatology, 2022
- Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic AssessmentDermatology and Therapy, 2020
- Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopeciaJournal of the American Academy of Dermatology, 2019
- Medical treatments for male and female pattern hair lossJournal of the American Academy of Dermatology, 2008
- The Pharmacokinetics of 2.5‐ to 10‐mg Oral Doses of Minoxidil in Healthy VolunteersThe Journal of Clinical Pharmacology, 1989
- Selective inhibition by minoxidil of prostacyclin production by cells in cultureBiochemical Pharmacology, 1988